Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

European Journal of Pharmacology
E NissinenI B Lindén

Abstract

Entacapone, a novel mainly peripherally acting catechol-O-methyltransferase inhibitor used in the treatment of Parkinson's disease, was evaluated for its possible uncoupling activity in cell culture, in rat liver mitochondria, and in isolated guinea-pig heart. Entacapone did not stimulate respiration in the L1210 murine T cell lymphoma cell line at the concentrations studied (5-40 microM). Furthermore, entacapone neither increased mitochondrial respiration nor impaired cardiac function at pharmacologically relevant concentrations (< 10 microM). In fact, the threshold concentration for increased mitochondrial oxygen consumption was 20 microM and half-maximal stimulation of respiration was not detected until 58 microM. Surprisingly, tolcapone, another catechol-O-methyltransferase inhibitor, which acts both peripherally and centrally, stimulated respiration in L1210 cells at the lowest concentration studied (5 microM). In addition, 1 microM tolcapone increased mitochondrial respiration, indicating that it caused uncoupling at a much lower concentration than that of 2,4-dinitrophenol, a well-known uncoupler of oxidative phosphorylation. Tolcapone also impaired the mechanical function and oxygen consumption of the isolated guinea-pi...Continue Reading

References

Jan 1, 1992·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·H YoshinoY Mizuno
Sep 1, 1992·Naunyn-Schmiedeberg's Archives of Pharmacology·E NissinenP Pohto
Apr 1, 1992·Brain : a Journal of Neurology·V M MannC D Marsden
Sep 29, 1989·Biochemical and Biophysical Research Communications·Y MizunoY Kagawa
Dec 1, 1989·Annals of Neurology·W D ParkerJ K Parks
Jun 3, 1989·Lancet·A H SchapiraC D Marsden
Jul 1, 1989·Lancet·L A BindoffD M Turnbull
Jul 1, 1989·Trends in Pharmacological Sciences·S OrreniusP Nicotera
Jan 1, 1985·Annual Review of Biochemistry·Y Hatefi
Dec 30, 1981·Biochimica Et Biophysica Acta·H Terada
Sep 1, 1995·British Journal of Clinical Pharmacology·J DingemanseP Van Brummelen
Sep 10, 1962·Biochimica Et Biophysica Acta·H C HEMKER

❮ Previous
Next ❯

Citations

Dec 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Alexander FisherAllan J McLean
Oct 24, 2002·European Journal of Pharmacology·Kristiina HaasioErkki Nissinen
Feb 27, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J P LarsenUNKNOWN NOMESAFE Study Group
Sep 15, 2012·Toxicological Sciences : an Official Journal of the Society of Toxicology·Russell T NavenNigel Greene
Sep 27, 2007·CNS Drug Reviews·Maria João BonifácioPatrício Soares-da-Silva
Feb 16, 2005·Expert Opinion on Drug Safety·Nuno Borges
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Katie ChanPeter J O'Brien
Nov 28, 2006·Expert Opinion on Drug Metabolism & Toxicology·John Cl Erve
Nov 28, 2006·Expert Opinion on Drug Metabolism & Toxicology·Michael J Liguori, Jeffrey F Waring
Dec 6, 2008·Biochemical and Biophysical Research Communications·Eiichi TsujiKei Takeda
Sep 28, 2005·Acta Cirúrgica Brasileira·George Emílio Sampaio BarretoRamon dos Santos El-Bachá
Jul 2, 2005·Critical Reviews in Toxicology·Jennie L WalgrenDavid C Thompson
Aug 16, 2002·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Kristina HaasioAntti Sukura
Aug 12, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nuno Borges
Nov 11, 1999·Current Opinion in Neurology·W Poewe
Mar 20, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Iain P HargreavesSimon J R Heales
May 19, 2009·Environmental and Molecular Mutagenesis·George BarretoLisandro Diego Alvarez-Giraldez
Feb 9, 2005·CNS Drugs·Gillian M Keating, Katherine A Lyseng-Williamson
Aug 9, 2003·Expert Opinion on Drug Safety·Reina Benabou, Cheryl Waters
Jan 30, 2019·Oxidative Medicine and Cellular Longevity·Alex France M MonteiroLuciana Scotti
Jul 21, 2020·Drug Discovery Today·Tiago Barros SilvaPatrício Soares-da-Silva
Dec 13, 2005·Journal of Medicinal Chemistry·David A LearmonthPatrício Soares-da-Silva
Mar 26, 2010·Journal of Medicinal Chemistry·László E KissDavid A Learmonth
Aug 1, 2014·Journal of Medicinal Chemistry·László E Kiss, Patrício Soares-da-Silva

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.